Get to know our clinical trials

Clinical trial to evaluate the efficacy and safety of Antinocabtagene Autoleucel in participants with newly diagnosed multiple myeloma.

THE AIM OF THIS STUDY IS TO INVESTIGATE THE SAFETY AND EFFICACY OF DARA-VRD (COHORT A) OR ISA- VRD (COHORTS B AND C) TREATMENT FOLLOWED BY ANITOCABTAGENE AUTOLEUCEL, A CAR-T THERAPY, COUPLED WITH LENALIDOMIDE MAINTENANCE TREATMENT (COHORTS A AND B) IN PATIENTS WITH NEWLY DIAGNOSED MM.

Imagen de la Dra. Paula Rodríguez Otero, especialista enHematología de la Clínica Universidad de Navarra. La Dra. Rodríguez se dedica preferencialmente al estudio y tratamiento del mieloma múltiple y el trasplante alogénico.
Dr. Paula Rodríguez Otero Curriculum
Specialist Hematology and Hemotherapy Department
Navarre headquarters
Madrid headquarters
Cancer Center
Hematologic Cancer Area
Status
In recruitment
headquarters
Pamplona/Madrid
Early phase

Technical Summary

  • PHASE II, OPEN-LABEL, MULTICENTER, MULTIPLE COHORT STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ANITOCABTAGENE AUTOLEUCEL IN PARTICIPANTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA.
  • Code EudraCT: 2024-517020-18-00
  • Protocol number: GEM-AnitoFIRST
  • Promoter: Fundación Pethema
  • Molecule/Drug: Antinocabtagene Autoleucel

* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.

Imagen de un icono azul con un fonendoscopio o estetoscopio.

Do you want to participate in this trial?

Request an appointment for our specialists to assess whether you qualify for this clinical trial

I want to make an appointment
Imagen de un icono azul de un registro en el informe médico.

Do you prefer to send us your reports?

If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.

I WANT TO REQUEST A SECOND OPINION